News Headlines Article

Study: Avastin didn’t extend life of breast cancer patients
USA Today

U.S. government health scientists said Friday that follow-up studies of a Roche breast cancer drug show it failed to slow tumor growth or extend patient lives, opening the door for a potential withdrawal in that indication. The Food and Drug Administration approved Roche’s blockbuster Avastin in 2008 based on early-stage trials showing it shrank tumors caused by breast cancer. The decision was controversial because drugs for cancer patients who have never been treated before must usually show evidence they extend lives.

Commands